• Record: found
  • Abstract: found
  • Article: not found

Improved outcomes of HIV-1-infected adults with tuberculosis in the era of highly active antiretroviral therapy.

AIDS (London, England)

Viral Load, AIDS-Related Opportunistic Infections, mortality, drug therapy, complications, Tuberculosis, Pulmonary, Tuberculosis, Treatment Outcome, Risk Factors, Prospective Studies, Middle Aged, Male, Humans, HIV-1, Female, Disease Progression, CD4 Lymphocyte Count, therapeutic use, Antitubercular Agents, methods, Antiretroviral Therapy, Highly Active, Anti-Retroviral Agents, Aged, 80 and over, Aged, Adult, Adolescent

Read this article at

      There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


      To compare the survival and treatment responses to antiretroviral therapy between HIV-1-infected patients with active TB (TB patients) and without (non-TB patients) in the era of highly active antiretroviral therapy (HAART). 8-year prospective observational study at a university hospital. A total of 125 (17.5%) TB patients (median CD4 cell count at TB diagnosis, 37 x 10(6) cells/l) and 591 non-TB patients (CD4 cell count at enrolment, 79 x 10(6) cells/l) were prospectively observed between June 1994 and October 2002. Virologic and immunologic responses were assessed in 230 antiretroviral-naive non-TB patients and 46 TB patients who concurrently initiated antituberculous therapy and HAART. The clinical outcome was evaluated by comparing incidence of new AIDS-associated opportunistic illnesses (OIs) and survival of all TB and non-TB patients. RESULTS Among antiretroviral-naive patients, CD4 cell count increase (71 versus 64 x 10(6) cells/l, P = 0.70) and proportions of patients achieving undetectable plasma viral load [20 of 46 versus 107 of 230, relative risk (RR), 0.93; 95% confidence interval (95% CI), 0.65-1.34; P = 0.71] at week 4 of HAART were similar between the 46 TB and 230 non-TB patients, as was the virologic failure during HAART (RR, 1.49; 95% CI, 0.92-2.41; P = 0.14). The risk for HIV progression to new OIs was also similar between the two groups (adjusted RR, 1.16; 95% CI, 0.764-1.77). The adjusted hazard ratio for death of TB patients compared with non-TB patients was 1.18 (95% CI, 0.65-2.32) before HAART era and 0.89 (95% CI, 0.57-1.69) in HAART era. Our data indicated that virologic, immunologic, and clinical responses to HAART and prognosis of HIV-1-infected TB patients who were concurrently treated with antituberculous therapy and HAART were similar to those of non-TB patients.

      Related collections

      Author and article information



      Comment on this article